Quest Diagnostics Incorporated Q2 FY2025 earnings call

• Strategy: Drove growth through innovative solutions, communicated at investor day in March. Raised full-year 2025 guidance due to strong Q2 results and utilization trends. • Growth drivers: Strong top-line growth (15.2%), 5.2% organic revenue growth from innovative clinical solutions, enterprise accounts, and acquisitions. Adjusted earnings per share grew 11.5% from top-line growth and productivity gains. • Channel performance: Physician channel had ~20% revenue growth (acquisitions + organic high single digits), hospital channel low single-digit growth with collaborative lab solutions, consumer channel strong growth with new offerings. • Advanced diagnostics: Double-digit growth in areas like advanced cardiometabolic, chronic kidney disease, autoimmune, brain health (AV detect blood test for Alzheimer's), and oncology (Haystack MRD market adoption). • Operational excellence: Targeting 3% annual cost savings via Invigorate program, deploying automation and AI, with front-end automation and automated accessioning platform pilots.

In the second quarter, consolidated revenues were $2.76 billion, up 15.2% versus the prior year. Consolidated organic revenues grew by 5.2%. Revenues for diagnostic information services were up 15.7% compared to the prior year. Total volume, measured by the number of requisitions, increased 16.3% versus the second quarter of 2024, with organic volume up 2.1%. Total revenue per requisition was down 0.4% versus the prior year, but on an organic basis, revenue per requisition was up 3.3%. Reported operating income in the second quarter was $438 million or 15.9% of revenues, while adjusted operating income was $466 million or 16.9% of revenues. Reported EPS was $2.47, and adjusted EPS was $2.62.

• Revenues expected to be between $10.8 billion and $10.92 billion. • Reported EPS expected in range of $8.60 to $8.80. • Adjusted EPS expected in range of $9.63 to $9.83. • Capital expenditures expected to be approximately $500 million. • Guidance reflects ~3.5% to 4% organic revenue growth plus acquisitions, operating margin expansion, and absorption of tariff impacts.

• Potential impact of uninsured population on volume, estimated ~30 to 40 basis point impact in 2026. • Uncertainty around PAMA changes, with potential $100 million pricing impact if not deferred. • Tariff impacts on supply chain, but manageable within guidance due to contracts and alternate sourcing.

Q: Ann Hynes asked about the Washington backdrop, including impact of uninsured and PAMA.

A: Jim Davis said impact on uninsured volume estimated ~30-40 basis points in 2026, minimal Medicaid impact. Sam Samad emphasized Medicaid impact immaterial in 2026 and 2027. On PAMA, pursuing reform and six-month delay, with bipartisan support.

Q: Kevin Caliendo asked about modernization investments and margins.

A: Sam Samad said modernization expenses bulk in second half, expecting operating margin expansion full year.

Q: Elizabeth Anderson asked about uninsured utilization and offset to headwinds.

A: Jim Davis said uninsured is small portion of revenue, majority find alternatives, 30 basis point impact on volume.

Q: Erin Wright asked about utilization trends into Q3.

A: Jim Davis said utilization consistent, driven by expanded access, advanced diagnostics, and weather impact.

Q: Michael Cherny asked about mix and organic rev per rec.

A: Jim Davis said majority offensive, driven by advanced diagnostics, functional medicine, CIT business.

Q: Patrick Donnelly asked about Q3 margins and PAMA financials.

A: Sam Samad said Q3 margin step down from Q2, PAMA impact ~$100M, will offset portion.

Q: Pito Chickering asked about tariffs.

A: Sam Samad and Jim Davis said tariff impact manageable via contracts and alternate sourcing.

Q: Jack Meehan asked about LifeLabs acquisition.

A: Sam Samad said ~8% of M&A contribution from LifeLabs, integration progressing well.

Q: David Westenberg asked about payer mix and wage increases.

A: Sam Samad said payer mix driven by LifeLabs acquisition, wage inflation 3%-4%, attrition down.

Q: Andrew Brackmann asked about functional medicine growth.

A: Jim Davis said sizable growth, driven by prevention, wellness, and podcasts.

Q: Noah Kava asked about revenue guidance breakdown.

A: Sam Samad said organic growth 3.5%-4%, acquisitions 6%-6.5%, driven by advanced tests and utilization.

Q: Aaron Wright asked about Haystack progress.

A: Jim Davis said good progress, positive oncologist feedback, growing business.

Q: Anna Krizinski asked about organic tests per day.

A: Jim Davis said driven by access expansion, advanced testing, and stabilized employer businesses.